Company News

New Study Demonstrates MyoStrain® Ability to Differentiate Between Varying Levels of Left Ventricular Hypertrophy to Help Optimize Therapy

July 22, 2021
Company News

MORRISVILLE, N.C., July 22, 2021 – Myocardial Solutions’ software platform, MyoStrain, was featured in a new Journal of Cardiovascular Magnetic Resonance publication evaluating a multiparametric assessment of left ventricular hypertrophy (LVH). LVH, which can be a result of an array of diseases and conditions, makes determining the cause of the hypertrophy crucial to implementing the most effective therapy. MyoStrain was able to detect and risk-stratify LVH patients, offering needed insights to clinicians for diagnostic and care purposes.[1]

The study compared MyoStrain versus traditional CMR metrics in its ability to evaluate different forms of LVH in athletes and patients with hypertensive heart disease (HHD), hypertrophic cardiomyopathy (HCM), and cardiac amyloidosis.[1]

Results demonstrated MyoStrain’s accuracy and reproducibility for the detection of cardiac dysfunction across multiple disease states and the potential in helping clinicians differentiate between endurance athletes and patients with HCM, HHD, or cardiac amyloidosis. This highlights MyoStrain's clinical utility in identifying patients in need of care based on the extent and severity of subclinical dysfunction.[1]

“MyoStrain has demonstrated the ability to risk stratify patients with similar symptoms and conditions to help physicians optimize therapy in patients with enlarged hearts.” said Jim Whayne, Chief Clinical Officer of Myocardial Solutions. Mr. Whayne went on to say, “For cardiac patients undergoing treatment, MyoStrain has the unique ability to detect subtle changes in heart health based on an established MyoHealth risk score. MyoHealth has the potential to impact cardiac patient care in multiple ways including early detection, risk stratification, and management of cardiac diseases.”

Access to the publication is available here.  

[1] Giusca, S., Steen, H., Montenbruck, M. et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson 23, 92 (2021). https://doi.org/10.1186/s12968-021-00775-8

Media Contact

Taylor Solomon
PR@myocardialsolutions.com
919.623.0973

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.